⚠ Clinical Disclaimer: These algorithms are clinical decision aids validated for non-valvular atrial fibrillation. OAC initiation must involve shared decision-making, considering patient values, absolute stroke risk, and absolute bleeding risk.
☞ Clinical Application & Nuances
1. Warning: NOACs in Rheumatic Heart Disease
⚠ Absolute Contraindication: In India, Rheumatic Heart Disease (RHD) remains highly prevalent, though the incidence is reducing. Patients with AFib and moderate-to-severe mitral stenosis (or mechanical heart valves) have "Valvular AF." NOACs (Apixaban, Rivaroxaban, Dabigatran) are strictly contraindicated in these patients as they fail to prevent valve thrombosis and stroke. You MUST prescribe a Vitamin K Antagonist (Warfarin/Acitrom) with INR monitoring.
2. The "Female Sex" Misconception
Female sex is a risk modifier, not an independent risk factor. In the absence of other CHA₂DS₂-VASc factors, a biological female scores a 1, but this does NOT confer significant stroke risk, and OAC is NOT recommended on this basis alone.
3. The R₂CHA₂DS₂-VASc Upgrade
Renal impairment is a potent, independent predictor of stroke in AFib. The R₂CHA₂DS₂-VASc score assigns 2 points for a Creatinine Clearance < 60 mL/min. This improves net reclassification, identifying high-risk patients who might otherwise falsely appear as 'low risk' on the standard scale.
4. The HAS-BLED Fallacy
A high HAS-BLED score (≥ 3) should never be used in isolation to deny a patient OAC if their stroke risk is high. It should be used to flag the need for closer monitoring and to actively correct modifiable bleeding risks (e.g., optimising BP, stopping NSAIDs, reducing alcohol intake).
5. NOACs vs. Warfarin (VKA)
- NOACs (Apixaban, Rivaroxaban, Dabigatran): Recommended as first-line therapy over Warfarin in eligible (non-valvular) patients with AFib due to a significantly lower risk of intracranial haemorrhage and no need for routine INR monitoring.
- Renal Dosing: All NOACs require dose reduction in severe renal impairment. Dabigatran is heavily renally cleared and should be avoided in severe CKD; Apixaban is the preferred choice in advanced kidney disease.
